About: Plant-based solutions for veterinary immunotherapeutics and prophylactics

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Plant-based solutions for veterinary immunotherapeutics and prophylactics Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Plant-based solutions for veterinary immunotherapeutics and prophylactics
Creator	Cox, Eric Conrad, Udo Devriendt, Bert Joensuu, Jussi Kolotilin, Igor Menassa, Rima Potter, Andrew Topp, Ed Warzecha, Heribert Hall, J Mcallister, Tim Mclean, Michael St, Eva
Source	Medline; PMC
abstract	An alarming increase in emergence of antibiotic resistance among pathogens worldwide has become a serious threat to our ability to treat infectious diseases according to the World Health Organization. Extensive use of antibiotics by livestock producers promotes the spread of new resistant strains, some of zoonotic concern, which increases food-borne illness in humans and causes significant economic burden on healthcare systems. Furthermore, consumer preferences for meat/poultry/fish produced without the use of antibiotics shape today’s market demand. So, it is viewed as inevitable by the One Health Initiative that humans need to reduce the use of antibiotics and turn to alternative, improved means to control disease: vaccination and prophylactics. Besides the intense research focused on novel therapeutic molecules, both these strategies rely heavily on the availability of cost-effective, efficient and scalable production platforms which will allow large-volume manufacturing for vaccines, antibodies and other biopharmaceuticals. Within this context, plant-based platforms for production of recombinant therapeutic proteins offer significant advantages over conventional expression systems, including lack of animal pathogens, low production costs, fast turnaround and response times and rapid, nearly-unlimited scalability. Also, because dried leaves and seeds can be stored at room temperature for lengthy periods without loss of recombinant proteins, plant expression systems have the potential to offer lucrative benefits from the development of edible vaccines and prophylactics, as these would not require “cold chain” storage and transportation, and could be administered in mass volumes with minimal processing. Several biotechnology companies currently have developed and adopted plant-based platforms for commercial production of recombinant protein therapeutics. In this manuscript, we outline the challenges in the process of livestock immunization as well as the current plant biotechnology developments aimed to address these challenges.
has issue date	2014-12-31(xsd:dateTime)
bibo:doi	10.1186/s13567-014-0117-4
bibo:pmid	25559098
has license	cc-by
sha1sum (hex)	b8915fde10e62d4b033a9141910e5639590f0bae
schema:url	https://doi.org/10.1186/s13567-014-0117-4
resource representing a document's title	Plant-based solutions for veterinary immunotherapeutics and prophylactics
has PubMed Central identifier	PMC4280687
has PubMed identifier	25559098
schema:publication	Vet Res
resource representing a document's body	covid:b8915fde10e62d4b033a9141910e5639590f0bae#body_text
is schema:about of	named entity 'PUBLICATION' named entity 'REFLECT' named entity 'EXPRESSED' named entity 'veterinary' named entity 'SOLE' named entity 'OPINIONS' named entity 'AUTHORS' named entity 'BASED' named entity 'PLANT-' named entity 'SOLUTIONS' named entity 'IMMUNOTHERAPEUTICS' named entity 'ITS' named entity 'COUNTRIES' named entity 'DO NOT' named entity 'ARGUMENTS' named entity 'VETERINARY' named entity 'GOVERNMENTS' named entity 'MEMBER' named entity 'EMPLOYED' named entity 'RESPONSIBILITY' named entity 'arguments' named entity 'solutions' named entity 'mice' named entity 'herpes virus' named entity 'VLPs' named entity 'fermentation' named entity 'downstream processing' named entity 'VLPs' named entity 'antibiotics' named entity 'tissue damage' named entity 'parenteral' named entity 'FcRn' named entity 'antigens' named entity 'fucose' named entity 'Research Triangle Park' named entity 'Parenteral' named entity '10 million' named entity 'respiratory tract' named entity 'public health' named entity 'mucosal' named entity 'antigens' named entity 'cross-pollination' named entity 'IgA' named entity 'Agrobacterium' named entity 'barley' named entity 'antigen' named entity 'livestock industry' named entity 'rice' named entity 'vaccinating' named entity 'plastome' named entity 'enterocytes' named entity 'antigens' named entity 'recombinant proteins' named entity 'ribosomal' named entity 'carbohydrate' named entity 'biologics' named entity 'antibiotics' named entity 'conjunctival' named entity 'H5N1' named entity 'mucosal' named entity 'mice' named entity 'antibodies' named entity 'urogenital' named entity 'seeds' named entity 'antibody' named entity 'nucleotide sequence' named entity 'secondary metabolites' named entity 'biomass' named entity 'intestinal tract'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software